Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the fast-growing obesity drug market.
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including reports of deaths and hospitalizations, while working with the FDA to resolve issues.
Those market dynamics will again be in focus when Novo reports results for its diabetes drug Ozempic and weight-loss ...
Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...
Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by ...
Fortune on MSN3d
Danish town where weight-loss wonder drug Ozempic is made suffers from the highest rates of overweight children in DenmarkA more tragic irony in the town is an obesity crisis among residents living in the shadow of the massive Wegovy-making plant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback